About our Society
Purpose of the Digital Therapeutics Society
The purpose of this society is to promote the use of digital technology in healthcare, particularly mobile applications and wearable devices. In recent years, a number of digital health systems utilizing information and communication technology (ICT) have been developed for the management and treatment of chronic diseases, and are already covered by insurance and provided in clinical practice in Europe and the United States. In Japan, SaMD (Software as Medical Device) has been approved for the treatment of smoking cessation, hypertension, and insomnia, and DTx is attracting attention as a new treatment method that can replace drugs. DTx is now being looked at as a new alternative to drugs.
Therefore, based on the activities and research experience of Representative Director Kayo Waki's Waki DTx Laboratory, this society has been established and is being operated to discuss the current status and issues of DTx and to speed up its implementation in society
Activities of the Society
Surveys and research on DTx
Organizing Lectures, Academic meetings, Panel discussion , Symposiums, etc
Publication of the Journal of the Society (Record of Activities)
Contact and cooperation with domestic and foreign organizations in our field
Policy recommendations for DTx popularization
Other activities necessary to achieve the purpose of the Society
Non-Member may join us, click here
Representative Director
Associate Professor, Department of Biomedical Informatics, Graduate School of Medicine, The University of Tokyo
Kayo Waki
| Director | Syunpei Ishikawa | Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo |
| Director | Kento Doi | The Department of Emergency and Critical care Medicine, Graduate School of Medicine, The University of Tokyo |
| Director | Imari Mimura | Division of Nephrology and Endocrinology, The University of Tokyo |
| Director | Naoyuki Kanda | Astellas Pharma Inc |
| Director | Gaku Sakaguchi | Shionogi & Co., Ltd |
| Director | Aya Yoshida | Raxi Co., Ltd |
What's Digital Therapeutics (DTx) ?
Digital Therapeutics (DTx) is a treatment method using software developed based on medical evidence. Through smartphone apps and newly developed devices, DTx provides personalized treatment and support for each patient.
DTx, which supports lifestyle improvement, is now covered by national insurance and is being introduced under the prescription of physicians. There are several DTxs currently under clinical trials. In addition, DTx is being introduced in ｍany foreign countries and is expected to be popularized in Japan as well.
Memorandum of intent
Please refer to memorandum of intent for the background and purpose of the Society.
Memorandum of intent[link]
Society Regulation
Society Regulation[link]
Activity Details
Activity Details[link]
Member List
Member List[link]
Non-Member may join us, click here